Sun Pharmaceutical Industries Ltd (Sun Pharma) is a global specialty generic pharmaceutical company. The company's primary activities include the manufacture and marketing of a broad spectrum of pharmaceutical formulations, including generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Sun Pharma serves a wide range of chronic and acute therapies and invests heavily in research and development. Sun Pharma's business portfolio is diverse and comprehensive. The company’s product portfolio includes generics, branded generics, speciality, difficult-to-make technology-intensive products, over-the-counter (OTC), anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and intermediates. Generic medications include tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Over-the-counter (OTC) products provide consumer health care products such as Revital (vitamins), Volini (topical analgesics), and Faringosept (sore throat). The company provides various Active Pharmaceutical Ingredients (APIs) that include anti-cancers, peptides, steroids, sex hormones, and controlled substances. It includes a specialty portfolio with innovative medicines in dermatology, ophthalmology, and onco-derm segments. The company also offers OTC medicines, including cough and sore throat medications, vitamins, topical analgesics, cold and flu remedies, analgesics, lifestyle products, and digestives. Sun Pharma manufactures Active Pharmaceutical Ingredients (APIs) for complex formulations, facilitating vertical integration. The company also has a presence in the consumer healthcare market, offering personal healthcare products without a prescription. Sun Pharma has 41 manufacturing facilities that support its operations and provide medicines to more than 100 countries worldwide. Sun Pharma's manufacturing facilities are in India, Hungary, the US, Israel, Australia, Japan, Canada, Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria, and Russia.

Sun Pharma continues to drive growth through a robust commitment to innovation. Its R&D capabilities are supported by a global network of six centers located in India, Israel, Canada, and the US, and a dedicated team of over 2,900 professionals. The company has focused on both Specialty and Innovative R&D, with 40% spending allocated to these areas. The Specialty R&D pipeline includes seven candidates in various stages of clinical trials, with notable products such as LEQSELVI, UNLOXCYT, NIDLEGYTM, ILUMYA, and FIBROMUN. The company has developed and filed 52 formulations for the Indian and regulated markets and submitted 183 dossiers in emerging markets. Additionally, over 100 drug master files have been filed across various markets. To support a diverse portfolio, the company focuses on strong R&D capabilities with an extensive commercial network, including tablets, capsules, injectables, sprays, ointments, creams, and liquids markets, effectively. The manufacturing infrastructure includes 40 facilities. In FY2025, the Company has also filed 100+ drug master files across various markets. In FY2025, the company incurred an R&D expense of INR31,342.8 million, which as a percentage of the company's revenue stood at 6.2%. The company submitted 659 ANDAs, 70 NDAs/BLAs, 529 DMFs/CEPs, and 3,229 patents for FY2025. From these filings, 542 ANDAs, 57 NDAs/BLAs, 401 DMFs/CEPs, and 2,459 patents were granted.